U.S. Paper and Forestry Products Stock News

If you have been watching First Citizens BancShares (FCNC.A), the company’s latest move deserves your attention. The bank just wrapped up a major part of its buyback program, purchasing 486,324 shares for over $916 million in four months. This brings total repurchases under the current plan to more than 1.6 million shares, or 11.5% of the company’s outstanding stock. This signals management’s strong conviction in the business and its long-term prospects. For investors, buybacks like these...

Deciding what to do with Cisco Systems (CSCO) right now feels like one of those classic investor crossroads. The company just released its fourth quarter and full-year earnings, revealing steady year-over-year growth in both revenue and net income. In addition, management provided guidance for fiscal 2026 that points to even more gains ahead, suggesting momentum may not fade anytime soon. For investors watching from the sidelines or holding on for the long haul, these consecutive positive...

If you are eyeing Emerson Electric stock and wondering if now is the time to buy, you are not alone. Investors have taken notice of this industrial stalwart after a series of price swings. EMR is up an impressive 28% over the last year and a remarkable 107% over the past five years. Even if you have only been watching the stock for a few months, you have probably seen it rise more than 11% in the past quarter despite a recent pullback of 8% over the last month. Much of this movement has been...

On August 12, 2025, Aflac announced it increased its share repurchase program authorization by 100 million shares, raising the total to 380 million shares. This substantial buyback expansion may reflect management's confidence in Aflac's ongoing financial strength and capital management approach. We'll explore how the expanded buyback authorization could influence Aflac's investment narrative, especially regarding future earnings per share growth. Trump's oil boom is here - pipelines are...

Occidental Petroleum Corporation recently provided updated third quarter 2025 production guidance, expecting output to reach 1.42 million to 1.46 million barrels of oil equivalent per day across all main operating areas. This signals continued operational momentum and a broad-based production increase, suggesting progress in efficiency and capacity expansion across Occidental's core assets. We'll examine how the higher production guidance adds weight to Occidental's investment narrative...

Thinking about what to do with PACCAR stock right now? You are not alone. Plenty of investors are eyeing this industrial leader and wondering whether all that long-term growth is already baked into the price, or if there is more upside waiting. The journey of PACCAR’s share price in the last year has been anything but boring. Despite some dips, the stock is still up nearly 6.5% over the past year and has more than doubled over the last five years—a seriously strong showing for a company in...

NasdaqGS:UNIT 1 Year Share Price vs Fair Value Explore Unity Group's Fair Values from the Community and select yours...

If you are sizing up your next move with Philip Morris International stock, you are not alone. Investors are watching closely as PM’s price journeys through a mix of steady returns and headline-driven bumps. Over the past year, PM has powered higher by nearly 50%, handily outpacing broader market indices and sparking conversation about whether this momentum can last. Looking at shorter timeframes, the story gets a bit more nuanced. PM is up around 2% this week, while the last month was...

Thinking about what to do with United Airlines Holdings stock right now? You are not alone. With the ticker UAL making eye-catching moves lately, investors are watching closely to see if the recent run has legs or if the ride is just beginning to hit turbulence. Let us talk numbers for a moment. Over the past three months, UAL has climbed more than 31%, and in the last year, total returns have soared nearly 138%. While some of that lift has come from broad travel demand bouncing back, there...

ZTO Express (Cayman) ( NYSE:ZTO ) Second Quarter 2025 Results Key Financial Results Revenue: CN¥11.8b (up 10% from 2Q...

If you’re eyeing General Motors stock and wondering whether now is the moment to get in, you’re not alone. GM has been on a steady climb that’s turning heads, up over 23% in the past year and nearly double over the last five. Recent weeks saw even more momentum, with the stock rising more than 15% in the past 90 days and almost 7% in the last month. That kind of move usually signals that something interesting is happening, whether it reflects confidence in long-term growth or a shift in how...

Trying to figure out what to do with your Lowe's Companies shares or considering jumping in? You are definitely not alone right now. With NYSE:LOW stock closing recently at $257.14, investors are looking for clues after a string of steady gains. Over the last month alone, Lowe's is up 16.4%, with a 14.9% bump over the last three months, and a remarkable 65.2% gain if you zoom out to the five-year timeframe. The company has grown annual revenue and net income recently, helping support those...

Disc Medicine, Inc. recently announced its financial results for the second quarter and first half of 2025, reporting a net loss of US$55.25 million for the quarter and US$89.33 million for the six-month period, both higher than the same periods last year. The widening losses highlight increased spending and may prompt questions among investors regarding the company’s path to profitability and resource allocation. We’ll now explore how Disc Medicine’s larger net loss shapes the company’s...

McCormick has recently expanded its lineup of limited-edition Finishing Sugars for fall and winter, introducing three new fall flavors and two new winter varieties alongside returning favorites, available both online and at retailers nationwide. Building on strong consumer demand from prior seasonal launches, the new and returning Finishing Sugars highlight McCormick’s ability to tap into seasonal trends and connect with customers seeking nostalgia and versatility in their culinary...

If you have been eyeing Broadcom’s stock lately, you are definitely not alone. The past year has been a whirlwind for AVGO, with the share price up more than 77% over the last twelve months. Even looking back over a longer stretch, it is hard not to be impressed: over the last five years, Broadcom’s total return has soared more than 860%. This kind of performance captures investors’ attention and prompts some big questions. Has the market gotten ahead of itself, or is there still value left...

It’s not every day that Cincinnati Financial (CINF) pops up on investors’ radars without a specific headline or major event driving discussion. That is exactly what is happening now, as a small uptick in the stock’s price has led some to wonder if this subtle move signals a turning point. For anyone trying to decide whether to hold, buy, or simply watch from the sidelines, even minor price shifts can open the door to bigger questions about what comes next. Looking at the bigger picture,...

OPKO Health recently advanced its Phase 1 Epstein-Barr virus vaccine trial and presented encouraging data for its oral GLP-1/glucagon dual agonist for obesity and MASH at ENDO 2025, while also announcing a plan to sell BioReference oncology and clinical testing assets to Labcorp to concentrate on its core businesses. This combination of clinical progress and repositioning initiatives highlights OPKO’s sharpened focus on developing high-impact treatments and strengthening its diagnostics...

Are you wondering what to do with Trimble stock right now? You are not alone. Whether you have been holding on for the long haul or you are considering dipping your toe in for the first time, Trimble’s recent performance certainly warrants a closer look. The stock has done some impressive climbing over the past year, gaining 42% in total return and even notching a 15% boost year-to-date. Granted, the last week has seen a slight pullback of about 5%, but that has not dimmed the bigger picture...

NYSE:IBTA 1 Year Share Price vs Fair Value Explore Ibotta's Fair Values from the Community and select yours Despite...

If you have been watching IQVIA Holdings, you are probably asking the same questions as many investors right now. Is this the moment to buy in, stay put, or wait until things cool off? IQVIA’s stock has had a dynamic run lately, which always gets attention when considering value and risk. Over the past month, IQVIA’s share price shot up by more than 20%, adding onto an impressive 39% total return over the last three months. Yet, when you zoom out, the picture is less rosy, with one-year...

The recent dip in MARA Holdings (MARA) may be giving investors pause, especially as crypto and blockchain-related stocks navigate ongoing uncertainty. Shares are down about 18% over the past month, following a bumpy year that has left many wondering if the market's risk appetite toward digital asset exposure is waning or simply recalibrating. With business fundamentals like revenue up 19% but net income showing a steep annual decline, the contrasting signals leave plenty of room for...

NasdaqGM:AURA 1 Year Share Price vs Fair Value Explore Aura Biosciences's Fair Values from the Community and select...

The recent dip in CSX (CSX) stock has caught the eye of many investors wondering if there is more to the story. With shares falling by over 1% in the last session, some are asking whether this movement signals new risk for the railway giant, or if it is a routine bout of volatility. The change is not tied to any major announcement or headline, making the situation even more interesting for those evaluating potential entry points. Over the past year, CSX has delivered moderate gains, posting...

Earlier this week, Axsome Therapeutics announced it received a Paragraph IV Certification Notice from Apotex related to a proposed generic version of Symbravo®, following Apotex’s Abbreviated New Drug Application filing with the FDA. This notice signals a potential challenge to Symbravo®’s intellectual property, raising questions for Axsome’s future market exclusivity and revenue streams. We’ll examine how this potential generic threat to Symbravo® could alter Axsome’s longer-term portfolio...